Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome?

P. Carratu, O. Resta
European Respiratory Journal 2008 31: 1381-1382; DOI: 10.1183/09031936.00008008
P. Carratu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Resta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Last year, L.M. Fabbri and K.F. Rabe published a very interesting article entitled “From COPD to chronic systemic inflammatory syndrome?” 1.

In the article, the authors clearly illustrated that chronic obstructive pulmonary disease (COPD) is not only an inflammatory chronic disease of the airway and the lungs, but also involves systemic, cellular and humoral inflammation, as well as systemic oxidative stress, with striking changes in vasomotor and endothelial functions. These systemic effects of smoking-induced COPD are also critically implicated in establishing associated cardiovascular and metabolic disorders. The presence of frequent complex comorbidities led the authors to consider COPD to be a predisposing condition for developing a new distinct disorder, called chronic systemic inflammatory syndrome (CSIS). Thus, according to the authors, the diagnosis of CSIS needs to be confirmed by the presence of at least three components from a panel of the six most frequent comorbidities that provoke clinical and functional abnormalities of respiratory, cardiovascular and metabolic systems 1.

More recently, the same authors wrote an interesting review on the complex chronic comorbidities of COPD 2. Of the frequent, complex, chronic comorbidities associated with COPD, we would like to highlight the important role of obstructive sleep apnoea (OSA), which actively participates in the development of CSIS. Important features of OSA are: a slow, progressive, severe evolution; the ability to impair, directly or indirectly, all target organs simultaneously; persistence, sustained by local and systemic inflammation; and association with clinically recognisable features, signs and symptoms. In addition, OSA shares several important features with COPD, as follows. 1) OSA affects ≤4–6% of all middle-aged males and 2% of middle-aged females, with percentages similar to COPD 3. 2) It is now appreciated by several well-controlled epidemiological studies that ∼20% of patients with OSA will have COPD 4, and ∼10% of OSA is disclosed in COPD patients independently of the degree of functional status 5. 3) In 63% of OSA patients a history of smoking is recorded, which is a predisposing factor for both OSA and COPD 5. 4) With regard to the cardiac and metabolic effects often reported in COPD, right cardiac failure and comorbidities in the left heart, including congestive failure and systemic hypertension, are often observed in OSA patients 6. Associated metabolic abnormalities, such as dyslipidaemia, insulin resistance and obesity, are also commonly present in these patients 5, indicating that OSA is characterised by signs and symptoms leading to systemic, clinical and functional abnormalities. 5) In addition, OSA is characterised by the presence of upper airway and systemic inflammation: there is evidence that circulating, local inflammatory and oxidative stress factors are constantly increased in OSA patients 7, 8, while further recent studies reported a strongly positive correlation between C-reactive protein and severity of OSA 9. The reason for increased inflammation in OSA is likely to be the activation of nuclear factor-κB by stress hypoxia and/or increased adipokines and free fatty acids, which are released by excess adipose tissue and represent the final common inflammatory pathway linking obesity, OSA and the metabolic syndrome, both individually and, in many cases, synergistically 10. 6) Finally, as regards the complications that modify the natural history of COPD, it has previously been shown that an augmented risk of developing respiratory failure, pulmonary hypertension and cor pulmonale exists in patients with OSA and COPD (overlap syndrome), compared with patients with only COPD, independently of the degree of airway obstruction 11.

For all these reasons, together with the evidence that both chronic obstructive pulmonary disease and obstructive sleep apnoea are more frequent among elderly individuals, we would like to stimulate discussion about the proposal to add obstructive sleep apnoea to the panel of the most frequent comorbidities and/or associations, which might seriously change the severity and prognosis of the newly coined chronic systemic inflammatory syndrome (table 1⇓).

View this table:
  • View inline
  • View popup
Table 1—

Diagnostic components of chronic systemic inflammatory syndrome

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007;370:797–799.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204–212.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Coughlin S, Calverley P, Wilding J. Sleep disordered breathing – a new component of syndrome x?. Obes Rev 2001;2:267–274.
      OpenUrlCrossRefPubMed
    4. ↵
      Fletcher EC. Chronic lung disease in the sleep apnea syndrome. Lung 1990; 168: Suppl., 751–761
    5. ↵
      Alam I, Lewis K, Stephens JW, Baxter JN. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2007;8:119–127.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:128–133.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Lavie L. Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Med Rev 2003;7:35–51.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002;122:1162–1167.
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Chung S, Yoon IY, Shin YK, et al. Endothelial dysfunction and C-reactive protein in relation with the severity of obstructive sleep apnea syndrome. Sleep 2007;30:997–1001.
      OpenUrlPubMedWeb of Science
    10. ↵
      Htoo AK, Greenberg H, Tongia S, et al. Activation of nuclear factor κB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006;10:43–50.
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995;151:82–86.
      OpenUrlCrossRefPubMedWeb of Science
    PreviousNext
    Back to top
    View this article with LENS
    Vol 31 Issue 6 Table of Contents
    European Respiratory Journal: 31 (6)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome?
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome?
    P. Carratu, O. Resta
    European Respiratory Journal Jun 2008, 31 (6) 1381-1382; DOI: 10.1183/09031936.00008008

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome?
    P. Carratu, O. Resta
    European Respiratory Journal Jun 2008, 31 (6) 1381-1382; DOI: 10.1183/09031936.00008008
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
    • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
    • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2022 by the European Respiratory Society